Back

Bifidobacterium pseudocatenulatum extracellular vesicles promote Ly6G+ granulocyte infiltration to inhibit melanoma tumour progression

Nicklin, A. D.; Jordan, A.; Price, C. A.; Rowe, M.; Ilker, N.; Mitchell, L.; Stentz, R.; Carding, S. R.; Hall, L. J.; Robinson, S. D.

2026-07-08 cancer biology
10.64898/2026.06.08.731027 bioRxiv
Show abstract

Harnessing the immunomodulatory capacity of commensal bacteria is an emerging avenue in cancer therapy. Bacterial extracellular vesicles (BEVs) provide a non-replicating, nanoscale alternative to live microbes with the potential for safer systemic delivery. Here, we investigated BEVs from a novel Gram-positive strain of Bifidobacterium pseudocatenulatum (Bif-210). Intravenous administration of Bif-210 BEVs reduced B16-F10 melanoma growth in C57BL/6J mice. Mechanistically, BEVs increased tumour-infiltrating Ly6G+ granulocytes in vivo, increased CD11b+Ly6G+ and ICAM-1+Ly6G+ bone marrow populations, and induced production of the neutrophil-attracting chemokines KC/CXCL1 (mouse) and IL-8 (human). Although Ly6G+ depletion independently inhibited tumour growth, it did not combine additively with BEVs, supporting a model in which Bif-210 BEVs alter Ly6G+ granulocyte function rather than simply expanding a conventional pro-tumour granulocyte pool. BEVs activated TLR2, did not activate TLR4, and upregulated TLR2 on Ly6G+ cells, while proxy assays provided no evidence of NETosis-associated activation. Repeated intravenous BEV administration produced no overt toxicity by tissue histology, body temperature, or body weight monitoring. These findings position B. pseudocatenulatum BEVs as a promising systemic immunotherapy that recruits and re-educates granulocytes via a TLR2-centred pathway to restrain melanoma progression. HIGHLIGHTSO_LIIntravenous Bif-210 BEVs reduce established B16-F10 melanoma growth in mice. C_LIO_LIBif-210 BEVs selectively increase tumour-associated Ly6G+ granulocytes. C_LIO_LIBEV treatment and Ly6G depletion are non-additive, linking BEV activity to granulocyte biology. C_LIO_LIBif-210 BEVs expand Ly6G+ bone marrow populations and induce granulocyte-recruiting chemokines. C_LIO_LIBif-210 BEVs engage TLR2 and enhance granulocyte fitness without NETosis-associated activation. C_LI

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 15%
12.1%
2
Cell Reports Medicine
153 papers in training set
Top 0.1%
9.9%
3
Journal of Extracellular Vesicles
55 papers in training set
Top 0.1%
9.9%
4
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 12%
4.4%
5
ACS Nano
113 papers in training set
Top 0.5%
4.1%
6
Biomaterials
84 papers in training set
Top 0.6%
2.8%
7
Journal of Controlled Release
44 papers in training set
Top 0.4%
2.7%
8
Cell Reports
1498 papers in training set
Top 15%
2.5%
9
Molecular Therapy Oncology
10 papers in training set
Top 0.1%
2.5%
50% of probability mass above
10
Science Advances
1243 papers in training set
Top 14%
2.4%
11
Cancer Cell
42 papers in training set
Top 0.7%
1.8%
12
Advanced Science
286 papers in training set
Top 5%
1.7%
13
EMBO Molecular Medicine
95 papers in training set
Top 0.9%
1.7%
14
Frontiers in Immunology
638 papers in training set
Top 6%
1.5%
15
ACS Central Science
71 papers in training set
Top 0.8%
1.5%
16
Molecular Cancer Therapeutics
40 papers in training set
Top 0.6%
1.1%
17
Science Translational Medicine
127 papers in training set
Top 2%
1.1%
18
eLife
5828 papers in training set
Top 56%
1.1%
19
Cell Stem Cell
62 papers in training set
Top 1%
1.1%
20
Nature Cancer
39 papers in training set
Top 1%
1.1%
21
Journal of Clinical Investigation
179 papers in training set
Top 4%
1.1%
22
Communications Biology
993 papers in training set
Top 20%
1.1%
23
iScience
1154 papers in training set
Top 28%
1.1%
24
Nature Biomedical Engineering
47 papers in training set
Top 1%
1.1%
25
Molecular Therapy
81 papers in training set
Top 1%
1.1%
26
Journal of Extracellular Biology
22 papers in training set
Top 0.2%
1.1%
27
British Journal of Cancer
49 papers in training set
Top 1%
1.0%
28
JCI Insight
277 papers in training set
Top 7%
1.0%
29
Cancer Immunology Research
35 papers in training set
Top 0.8%
0.9%
30
EMBO Reports
263 papers in training set
Top 7%
0.9%